Premium
Immune thrombocytopenia among patients with cancer and its response to treatment
Author(s) -
Ayesh Haj Yousef Mahmoud H.,
Alawneh Khaldoon,
Zahran Deeb,
Aldaoud Najla H.,
Khader Yousef
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13091
Subject(s) - medicine , cancer , immune thrombocytopenia , immune system , university hospital , medical record , multivariate analysis , platelet , immunology
Objectives The aim of this study was to determine the rate of immune thrombocytopenia ( ITP ) in adult Jordanian patients diagnosed with cancer, to correlate this rate with the type of cancer and to assess the response of ITP in patients with cancer to treatment. Methods All adult patients aged 16 years or older who had been diagnosed with cancer at King Abdullah University Hospital ( KAUH ) between September 2002 and October 2017 were included in this study. Their medical records were reviewed for the diagnosis of ITP . Results The total number of patients diagnosed with cancer at KAUH between September 2002 and October 2017 was 8318. The majority of patients had solid cancers (87.0%), and hematological cancers constituted 13%. Fifteen (0.2%) patients with cancer had ITP . ITP was significantly more common in patients with lymphomas (1.3%) than in patients with solid cancers (0.1%) ( P < .005). In the multivariate analysis and after adjusting for age and gender, patients with lymphomas were 15.2 times more likely to be diagnosed with ITP than were patients with solid cancer. Conclusions Patients with lymphomas had higher rates of ITP than did patients with solid cancers. Treatment of ITP ‐associated cancer may improve the platelets count.